MRNA Relative Valuation
MRNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRNA is overvalued; if below, it's undervalued.
Historical Valuation
Moderna Inc (MRNA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.52. The fair price of Moderna Inc (MRNA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：25.18
Fair
-3.03
PE
1Y
3Y
5Y
Trailing
Forward
-1.53
EV/EBITDA
Moderna Inc. (MRNA) has a current EV/EBITDA of -1.53. The 5-year average EV/EBITDA is -1.90. The thresholds are as follows: Strongly Undervalued below -21.41, Undervalued between -21.41 and -11.65, Fairly Valued between 7.86 and -11.65, Overvalued between 7.86 and 17.62, and Strongly Overvalued above 17.62. The current Forward EV/EBITDA of -1.53 falls within the Historic Trend Line -Fairly Valued range.
-1.14
EV/EBIT
Moderna Inc. (MRNA) has a current EV/EBIT of -1.14. The 5-year average EV/EBIT is -0.86. The thresholds are as follows: Strongly Undervalued below -17.99, Undervalued between -17.99 and -9.42, Fairly Valued between 7.70 and -9.42, Overvalued between 7.70 and 16.27, and Strongly Overvalued above 16.27. The current Forward EV/EBIT of -1.14 falls within the Historic Trend Line -Fairly Valued range.
5.28
PS
Moderna Inc. (MRNA) has a current PS of 5.28. The 5-year average PS is 6.23. The thresholds are as follows: Strongly Undervalued below 0.74, Undervalued between 0.74 and 3.48, Fairly Valued between 8.98 and 3.48, Overvalued between 8.98 and 11.72, and Strongly Overvalued above 11.72. The current Forward PS of 5.28 falls within the Historic Trend Line -Fairly Valued range.
-4.22
P/OCF
Moderna Inc. (MRNA) has a current P/OCF of -4.22. The 5-year average P/OCF is -3.48. The thresholds are as follows: Strongly Undervalued below -32.20, Undervalued between -32.20 and -17.84, Fairly Valued between 10.88 and -17.84, Overvalued between 10.88 and 25.24, and Strongly Overvalued above 25.24. The current Forward P/OCF of -4.22 falls within the Historic Trend Line -Fairly Valued range.
-3.73
P/FCF
Moderna Inc. (MRNA) has a current P/FCF of -3.73. The 5-year average P/FCF is -2.23. The thresholds are as follows: Strongly Undervalued below -32.05, Undervalued between -32.05 and -17.14, Fairly Valued between 12.68 and -17.14, Overvalued between 12.68 and 27.59, and Strongly Overvalued above 27.59. The current Forward P/FCF of -3.73 falls within the Historic Trend Line -Fairly Valued range.
Moderna Inc (MRNA) has a current Price-to-Book (P/B) ratio of 1.06. Compared to its 3-year average P/B ratio of 2.29 , the current P/B ratio is approximately -53.98% higher. Relative to its 5-year average P/B ratio of 6.12, the current P/B ratio is about -82.76% higher. Moderna Inc (MRNA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -14.09%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.70% , the current FCF yield is about -100.00% lower.
1.07
P/B
Median3y
2.29
Median5y
6.12
-26.97
FCF Yield
Median3y
-14.09
Median5y
-3.70
Competitors Valuation Multiple
The average P/S ratio for MRNA's competitors is , providing a benchmark for relative valuation. Moderna Inc Corp (MRNA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -45.44%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MRNA decreased by 38.70% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.10 to -3.17.
The secondary factor is the Revenue Growth, contributed -45.44%to the performance.
Overall, the performance of MRNA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Moderna Inc (MRNA) currently overvalued or undervalued?
What is Moderna Inc (MRNA) fair value?
How does MRNA's valuation metrics compare to the industry average?
What is the current P/B ratio for Moderna Inc (MRNA) as of Dec 05 2025?
What is the current FCF Yield for Moderna Inc (MRNA) as of Dec 05 2025?
What is the current Forward P/E ratio for Moderna Inc (MRNA) as of Dec 05 2025?